BioNexus Gene Lab Corp is a publicly traded biotechnology company specializing in gene lab industry, with headquarters in Kuala Lumpur, Malaysia, listed on Nasdaq, and involved in biotech operations.

# Company Summary: BioNexus Gene Lab Corp

**Overview:**
- Name: BioNexus Gene Lab Corp
- Incorporation: Wyoming
- Head Office: Level 28, Tower A, Menara UOA Bangsar, No. 5 Jalan Bangsar Utama 1, Kuala Lumpur, Malaysia 59000
- Phone: +1 307 241 6898
- Stock Listing: Nasdaq Capital Market (Ticker: BGLC)

**Type of Business:**
- The exact nature of the company's operations is not explicitly detailed in the provided document.
- The company appears to be involved in the biotechnology or gene lab industry, suggested by its name, "BioNexus Gene Lab Corp."

**Financial and Operational Details:**
- As of June 30, 2024, the market value of the company's common stock held by non-affiliates was approximately $8,184,480, based on 17.2 million shares at a last reported sales price of $0.4752.
- Number of Shares Outstanding (as of December 31, 2024): Not specified in the provided excerpt.
- Revenue, net income, number of customers, employees, or other detailed operational metrics are not provided in this document.

**Regulatory and Filing Status:**
- The company filed an Annual Report (Form 10-K) for the fiscal year ended December 31, 2024.
- The filing indicates the company is a "smaller reporting company" and an "emerging growth company."
- The company has not submitted certain filings electronically, as indicated by the "No" responses on submission of Interactive Data Files and internal control assessments.

**Additional Notes:**
- The document is an amendment (No. 1) to the original 10-K, primarily to file its Policy on Recovery of Erroneously Awarded Compensation ("Clawback Policy").
- No specific operational or financial performance figures such as revenue, net income, employee count, or customer numbers are included in the excerpt provided.

**Conclusion:**
Based on the provided filing, detailed specifics regarding BioNexus Gene Lab Corp's operations, such as revenue, number of employees, or dedicated customer base, are not disclosed. The company appears to be in the biotechnology sector, with a focus on gene labs, and is publicly traded on Nasdaq.

bglc_10ka.htm





UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

Amendment No.1
FORM 10-K/A

(Mark One)

☒     ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the fiscal year ended: December 31, 2022

or

☐     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the transition period from ________ to ________

Commission File Number: 001-41750


BIONEXUS GENE LAB CORP. 
------------------------------------------------------
(Exact name of registrant as specified in its charter)



Wyoming | 35-2604830 
--------------------------------------------------------------+------------------------------------
(State or Other Jurisdiction ofIncorporation or Organization) | (I.R.S. EmployerIdentification No.)
Unit 02, Level 10, Tower B, Avenue 3, The Vertical | 
Business Suite II, Bangsar South | 
8 Jalan Kerinchi | 
Kuala Lumpur, Malaysia | 59200 
(Address of Principal Executive Offices) | (Zip Code) 


+1 307 241 6898
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class | Trading Symbol(s) | Name of each exchange where registered
---------------------------+-------------------+---------------------------------------
Common Stock, no par value | BGLC | Nasdaq Capital Market 


Securities registered pursuant to Section 12(g) of the Act: 
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer | ☐ | Accelerated filer | ☐
------------------------+---+---------------------------+--
Non-accelerated Filer | ☒ | Smaller reporting company | ☒
 | | Emerging growth company | ☒


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of December 31, 2022, the aggregate market value of shares held by non-affiliates of the registrant was approximately $ 48,487,449. 

As of the December 31, 2022, there were 173,718,152 shares of common stock, no par value, outstanding.






Explanatory Note

This Amendment No. 1 on Form 10-K/A (the “Amendment”) amends the Annual Report on Form 10-K of BIONEXUS GENE LAB CORP. (the “Company”) for the fiscal year ended December 31, 2022 (the “Original Filing”). This Amendment is being filed solely to amend and restate in its entirety Part II., Item 9A. Controls and Procedures of the Prior Filing. 

This filing is in response to a Comment Letter from the Staff of the Securities and Exchange Commission. 

Other than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information in the Original Filing or reflect any events that have occurred after the Original Filing was made. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original Filing was made. No changes have been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment should be read together with the Original Filing and the Company’s other filings with the SEC.


2


Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this annual report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of December 31, 2022. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were not effective in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was not accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures. The Company’s disclosure controls and procedures were not effective due to the fact that the Part II., Item 9A Controls and Procedures in the Original Filing were inaccurate.  

Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:


· | Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;
--+---------------------------------------------------------------------------------------------------------------------------------------------------------



· | Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the board of directors; and
--+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



· | Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
--+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



3


Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013) as set forth in its Internal Control - Integrated Framework. This assessment concluded that the internal control over financial reporting were effective. 


The Original Filing, however, stated that management concluded there was a material weakness in our internal control over financial reporting based up the following;
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
- | We were unable to maintain segregation of duties within our business operations due to our reliance on a single individual fulfilling the role of sole officer and director. 
- | Lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal control and procedures.


We made a mistake and the above basis for identifying a material weakness was inaccurate. In fact, at the time of the Original Filing, the Company did not have a sole officer and director, rather it had five officers and four directors. In addition, the Company had established an audit committee comprised of three independent directors.  

This annual report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

Changes in Internal Controls over Financial Reporting

During the year ended December 31, 2022, there has been no change in internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Item 6. Exhibits.


Exhibit | Description 
--------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
31.1 | Certification of the Company’s Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) 



4


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


BIONEXUS GENE LAB CORPORATION 
----------------------------------------------------------------------------------
/s/ Su-Leng Tan Lee 
Su-Leng Tan Lee 
Chief Executive Officer(Principal Executive Officer) 
/s/ Su-Leng Tan Lee 
Su-Leng Tan Lee 
Acting Chief Financial Officer (Acting Principal Financial and Accounting Officer)

 May 31, 2024


5




Bionexus Gene Lab Corp. is a biotechnology company specializing in advanced genetic and genomic solutions for molecular diagnostics, research, and personalized medicine.

## Company Overview: Bionexus Gene Lab Corp.

### Description
Bionexus Gene Lab Corp. is a biotechnology company focused on the development and commercialization of advanced genetic and genomic solutions. Their primary mission is to provide innovative technologies and products in the areas of molecular diagnostics, research and development in genomics, and personalized medicine. 

### Key Areas of Focus
- **Molecular Diagnostics**: Developing assays and kits for the detection of genetic and infectious diseases.
- **Research and Development**: Conducting extensive research to facilitate advancements in gene therapy and regenerative medicine.
- **Personalized Medicine**: Tailoring healthcare solutions based on individual genetic profiles.

### Financials
- **Revenue**: Specific revenue figures for the fiscal year ending December 31, 2022, are not mentioned in the document provided.
- **Income**: The document does not outline income figures directly, indicating a need for further financial statements to extract this detail.

### Customer Base
- The document does not specifically state the number of customers. However, it implies engagement with healthcare providers and institutions needing genomic solutions.

### Employment
- Bionexus Gene Lab Corp. employs a team of five officers and four directors to manage its operations and strategic direction, totaling **nine key personnel** in leadership roles.

### Additional Information
- **Location**: The company is headquartered at Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangsar South, Kuala Lumpur, Malaysia.
- **Trading Symbol**: Common Stock listed under the symbol **BGLC** on the Nasdaq Capital Market.

### Overall Assessment
Bionexus Gene Lab Corp. operates in a highly specialized sector with a focus on using genetic insights to advance healthcare; however, additional financial specifics could provide a clearer picture of its performance and market position.

BioNexus Gene Lab Corp

10-K / April 29, 2025

10-K / May 31, 2024

10-K / April 29, 2025

Company Summary: BioNexus Gene Lab Corp